These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 25108545

  • 21. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing.
    Kempsford RD, Oliver A, Bal J, Tombs L, Quinn D.
    Respir Med; 2013 Dec; 107(12):1873-80. PubMed ID: 24200619
    [Abstract] [Full Text] [Related]

  • 22. Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma.
    Oliver AJ, Covar RA, Goldfrad CH, Klein RM, Pedersen SE, Sorkness CA, Tomkins SA, Villarán C, Grigg J.
    J Pediatr; 2016 Nov; 178():246-253.e2. PubMed ID: 27622699
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 24. The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma.
    Kempsford RD, Bal J, Baines A, Renaux J, Ravindranath R, Thomas PS.
    Respir Med; 2016 Mar; 112():18-24. PubMed ID: 26823210
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y, Hozawa S, Sagara H, Ohbayashi H, Lee LA, Crawford J, Tamaoki J, Nishi T, Fowler A.
    Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
    [Abstract] [Full Text] [Related]

  • 26. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 27. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I, Williams M, Power S, Pilcher J, Weatherall M, Baines A, Moynihan J, Kempsford R, Beasley R, FF/VI Study Team.
    Respir Med; 2016 Oct; 119():115-121. PubMed ID: 27692131
    [Abstract] [Full Text] [Related]

  • 28. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
    Bateman ED, O'Byrne PM, Busse WW, Lötvall J, Bleecker ER, Andersen L, Jacques L, Frith L, Lim J, Woodcock A.
    Thorax; 2014 Apr; 69(4):312-9. PubMed ID: 24253831
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
    Zheng J, de Guia T, Wang-Jairaj J, Newlands AH, Wang C, Crim C, Zhong N.
    Curr Med Res Opin; 2015 Jun; 31(6):1191-200. PubMed ID: 25830381
    [Abstract] [Full Text] [Related]

  • 31. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.
    O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, Lötvall J.
    Eur Respir J; 2014 Mar; 43(3):773-82. PubMed ID: 24136330
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D.
    Respir Res; 2020 May 29; 21(1):131. PubMed ID: 32471423
    [Abstract] [Full Text] [Related]

  • 34. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.
    Boonsawat W, Goryachkina L, Jacques L, Frith L.
    Clin Drug Investig; 2008 May 29; 28(2):101-11. PubMed ID: 18211118
    [Abstract] [Full Text] [Related]

  • 35. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.
    ZuWallack R, Adelglass J, Clifford DP, Duke SP, Wire PD, Faris M, Harding SM.
    Chest; 2000 Aug 29; 118(2):303-12. PubMed ID: 10936117
    [Abstract] [Full Text] [Related]

  • 36. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
    van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, Noga O, Richard A, de Los Reyes A, Shu X, Pethe A, Tanase AM, D'Andrea P, PALLADIUM trial investigators.
    Lancet Respir Med; 2020 Oct 29; 8(10):987-999. PubMed ID: 32653075
    [Abstract] [Full Text] [Related]

  • 37. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 29; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 38. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L, Kerwin E, Collison K, Nelsen L, Wu W, Yang S, Pascoe S.
    Respir Med; 2017 Oct 29; 131():148-157. PubMed ID: 28947022
    [Abstract] [Full Text] [Related]

  • 39. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older.
    Raphael G, Yiu G, Sakov A, Liu S, Caracta C.
    J Asthma; 2018 Jun 29; 55(6):640-650. PubMed ID: 28763243
    [Abstract] [Full Text] [Related]

  • 40. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
    Busse WW, O'Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED.
    Thorax; 2013 Jun 29; 68(6):513-20. PubMed ID: 23440247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.